Audience: Individuals Performing COVID-19 Testing
Level: Laboratory Alert
After December 31, 2021, CDC will withdraw the request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of the CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel, the assay first introduced in February 2020 for detection of SARS-CoV-2 only. CDC is providing this advance notice for clinical laboratories to have adequate time to select and implement one of the many FDA-authorized alternatives.
Visit the FDA website for a list of authorized COVID-19 diagnostic methods. For a summary of the performance of FDA-authorized molecular methods with an FDA reference panel, visit this page.
In preparation for this change, CDC recommends clinical laboratories and testing sites that have been using the CDC 2019-nCoV RT-PCR assay select and begin their transition to another FDA-authorized COVID-19 test.
CDC encourages laboratories to consider adoption of a multiplexed method that can facilitate detection and differentiation of SARS-CoV-2 and influenza viruses.
Such assays can facilitate continued testing for both influenza and SARS-CoV-2 and can save both time and resources as we head into influenza season. Laboratories and testing sites should validate and verify their selected assay within their facility before beginning clinical testing.
CDC press release /21Jul2021
村松社長
最新記事 by 村松社長 (全て見る)
- 欧州の老舗航空会社がまたまた去ることに - 2024年10月22日
- ボーイング社最新鋭機の納期が遅れるならエアーバス社のでええやん - 2024年10月21日
- イタリア旅行と言えば - 2024年10月21日
- やっと終わりが見えたボーイング社の機械工のストライキ - 2024年10月20日
- 日本人は現在も中国大陸への旅行には、査証(ビザ)を中国政府の日本での出先機関で出向きビザの付与を受けなければならないが、1997年7月1日から中国支配(特別行政「SpecialAdministrativeRegion」)に変わった香港では、その支配下前と同様に無査証(いわゆるノービザ)で入国が出来る - 2024年10月20日